HK2 and neoplasm: For instance, the treatment of orthotopic tumours established from hypoxic pre-conditioned MDA-MB-231 cells with EGFR-targeted nanoparticles (NPs) loaded with paclitaxel and lonidamine, which is an inhibitor of hexokinase-2 that catalyses the phosphorylation of glucose to yield glucose 6-phosphate during the glycolysis, has been observed to reduce the tumour growth relative to NPs loaded with single agent [75].